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Abstract
Background: The enrichment of diet with nutrients with potential benefits on body composition is a strategy to
combat obesity. Conjugated linoleic acid (CLA) due its beneficial effects on body composition and inflammatory
processes becomes an interesting candidate, since the promotion and impairment of obesity is closely linked to a
low-grade inflammation state of adipose tissue. Previously we reported the favourable effects of moderate doses of
CLA mixture on body composition and inflammatory status of adipose tissue in mice fed a standard-fat diet. In the
present study we assessed the potential beneficial effects of CLA mixture (cis-9, trans-11 and trans-10, cis-12, 50:50)
in mice fed a high-fat diet.
Methods: Two doses were assayed: 0.15 g (CLA1) and 0.5 g CLA/kg body weight (CLA2) for the first 30 days of the
study and then animals received a double amount for another 35 days.
Results: The lowest dose (CLA1) had minor effects on body composition, plasma parameters and gene expression.
However, a clear reduction in fat accumulation was achieved by CLA2, accompanied by a reduction in leptin,
adiponectin and non-esterified fatty acids (NEFA) plasma concentrations. Insulin sensitivity was maintained despite
a slight increase in fasting glucose and insulin plasma concentrations. The study of gene expression both in
adipocytes and in the stromal vascular fraction (SVF) suggested that CLA may reduce either the infiltration of
macrophages in adipose tissue or the induction of expression of pro-inflammatory cytokines.
Conclusion: In conclusion, the use of moderate doses of an equimolar mix of the two main CLA isomers reduces
body fat content, improves plasma lipid profile, maintains insulin sensitivity (despite a moderate degree of
hyperinsulinaemia) without the promotion of inflammatory markers in adipose tissue of mice fed a high-fat diet.
Background
CLA refers to a group of positional and geometric iso-
mers of linoleic acid and has been extensively studied
due to its potential beneficial effects in several diseases
including cancer, atherosclerosis, diabetes and obesity
[1,2]. It has been suggested that the anti-carcinogenic
and anti-atherosclerosis effect of CLA stems from its
anti-inflammatory properties. One of the mechanisms
proposed by which CLA could exert its anti-inflamma-
tory effect is by the negative regulation of gene
expression of inflammation mediators [3]. The increased
size of adipose depots in obesity is related to a certain
degree of inflammation which may be involved in the
pathophysiology of obesity-associated disorders. This
low-grade inflammatory state has been associated with
the progressive infiltration of macrophages into adipose
tissue, which may be the main source of pro-inflamma-
tory cytokines and associated insulin resistance in obe-
sity [4,5]. Furthermore, most studies conducted in
animals demonstrated that CLA reduces body fat mass
[6] with the trans-10, cis-12 CLA isomer mainly respon-
sible for this effect [1,7]. Therefore CLA, due to its ben-
eficial potential effects on both body composition and
* Correspondence: andreu.palou@uib.es
University of the Balearic Islands, Cra Valldemossa Km 7,5, E-07122, Palma de
Mallorca, Spain
Parra et al. Nutrition & Metabolism 2010, 7:5
http://www.nutritionandmetabolism.com/content/7/1/5
© 2010 Parra et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.inflammation, becomes an interesting nutritional strat-
egy in the treatment of obesity. However, in some stu-
dies conducted in mice —the most sensitive species—
fat loss triggered by CLA was accompanied by deleter-
ious side effects such as insulin resistance, hyperinsuli-
naemia and liver steatosis [8-11]. Both beneficial and
detrimental effects of CLA supplementation are more
modest or less evident in human studies. However, a
recent meta-analysis of human studies supports a mod-
est effect of CLA reducing body fat [12].
Controversial results about the anti-inflammatory
properties of CLA also exist. In vitro data demonstrate
that trans-10, cis-12 CLA activates NFB- and ERK1/2-
dependent IL-6, IL-8, and TNFa production, which
impairs adipogenic gene expression and glucose uptake
[13]. Furthermore, supplementation with trans-10, cis-12
CLA promotes macrophage infiltration into adipose tis-
sue, contributing to adipose tissue inflammation and
insulin resistance [14]. In contrast, treatment with cis-9,
trans-11 CLA reduces macrophage infiltration and
attenuates the inflammatory profile of obese adipose tis-
sue [15]. Interestingly, we have shown that the use of
moderate doses of an approximately equimolar mixture
of both main CLA isomers achieves a modest reduction
of fat gain, ameliorates macrophage infiltration into adi-
pose tissue and expression of pro-inflammatory cyto-
kines, therefore, contributing to preserve adipose
function [16].
In the present study, we analyze the potential effects
of moderate doses of CLA mixture on body composition
and insulin sensitivity, as well as on adipose tissue
inflammatory profile in mice fed a high-fat diet.
Methods
Animals
Male mice (C57BL/6J) from Charles River (Barcelona,
Spain) were housed in groups of four in plastic cages,
acclimated to 22°C with a 12 h light/12 h dark cycle.
Animals were fed ad libitum with a high-fat diet
(D12451, Research Diets Inc, New Brunswick) which
contains 45% calorie content as fat, 35% calorie content
as carbohydrate and the remaining 20% as protein. Food
intake and body weight were recorded every three days
during the experiment. Total calories consumed was
measured for each cage and expressed as the average of
the two cages per group. Fresh food was provided to the
mice biweekly. At 30 days of treatment, animals were
starved for 3 h, tail blood samples were obtained to per-
form plasma determinations and were then submitted to
the insulin tolerance test (ITT). 35 days later, animals
were sacrificed under fasting conditions (10 h).
All experimental procedures were performed accord-
ing to both national and institutional guidelines for ani-
mal care and use.
CLA Treatment
The CLA used was Tonalin® TG 80 derived from saf-
flower oil (kindly provided by Cognis). Tonalin is com-
posed of triglycerides containing approximately 80%
CLA with a 50:50 ratio of the active CLA isomers cis-9,
trans-11 and trans-10, cis-12.
Mice weighing 20 ± 0.2 g (5-week-old) were randomly
assigned to three experimental oral treatments: sun-
flower oil (control group, n = 8), CLA1 (n = 8) or CLA2
(n = 8) for 65 days. For the first 30 days, two doses of
CLA were assessed: CLA1 (0.15 g CLA/kg body weight)
and CLA2 (0.50 g CLA/kg body weight), taking the
weight of the animals at the beginning of the experi-
ment as a reference. After 30 days of treatment and
until the end of the experiment, the corresponding dose
of each group was doubled. Therefore, animals received
a daily amount of Tonalin equivalent to 3 mg CLA/ani-
mal in CLA1 group and 10 mg/animal in CLA2 group
for the first 30 days and 6 mg CLA/animal in CLA1
group and 20 mg/animal in CLA2 group for the last 35
days of treatment. An adequate amount of commercial
sunflower oil was given to the animals to achieve isoca-
loric load between groups.
Insulin tolerance test
ITT was performed on day 30 of the study after 3 h fast.
Recombinant human insulin (Humulin R; Eli Lilly,
Spain), previously diluted in 0.9% saline, was intraperito-
neally injected (0.8 U/kg body weight). Blood glucose
concentration was determined from tail blood samples
before and at 15, 30, 60, 90, and 120 min postinjection
using an Accu Check Sensor (Roche Diagnostics, Barce-
l o n a ,S p a i n ) .T h ea r e au n d e rt h ec u r v ef o re a c hm i c e
was calculated using the KaleidaGraph software version
3.0 (Synergy Software, Reading, PA, U.S.A.), and the
mean value ± SEM calculated for each group.
Sacrifice and tissue sampling
Mice were anaesthetised by intraperitoneal injection of a
m i x t u r eo fx i l a c i n e( 1 0m g / k gb o d yw e i g h t )a n dk e t a -
mine (100 mg/kg body weight) and blood was collected
by cardiac puncture. Liver, brown and white adipose
depots were rapidly removed, weighed, rinsed with sal-
ine containing 0.1% diethyl pyrocarbonate (Sigma,
Madrid, Spain), frozen with nitrogen liquid and stored
at -70°C. Blood collected by cardiac puncture with
heparinized syringe and needle (0.2% heparin diluted
with saline, Sigma, Madrid, Spain) was centrifuged at
1000 g for 10 min at 4°C and plasma obtained was
stored at -70°C for later analysis.
Plasma analysis
Adiponectin and insulin plasma concentrations were
measured using a rat/mouse adiponectin ELISA kit
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lin Mouse Ultrasensitive ELISA kit (DRGInstruments
GmbH, Marburg, Germany) respectively. Resistin and
leptin plasma concentrations were also assessed by
ELISA using the following commercial kits: Mouse
Resistin Quantikine ELISA kit and Mouse Leptin Quan-
tikine ELISA kit (R&D Systems, Minneapolis, MN,
USA). Commercial enzymatic colorimetric kits were
used for the determination of plasma NEFA (Wako
Chemicals GmbH, Neuss, Germany) and circulating
concentrations of triglycerides (Sigma Diagnostics,
Madrid, Spain).
Hepatic triglyceride quantification
A sample of liver (200-300 mg) was homogenized in
PBS (1:2, wt:v) using a polytron homogenizer. Homoge-
nates were centrifuged at 500 g for 10 min and the
supernatant was used for the quantification. Total trigly-
ceride levels were measured using a commercial enzy-
matic colorimetric kit following standard procedures
(Sigma Diagnostics, Madrid, Spain).
Isolation of mature adipocytes and SVF from epididymal
fat depots
Fresh epididymal white adipose tissue was digested with
collagenase and after filtration and washing steps the
SVF and the mature adipocyte-enriched fraction were
obtained following the protocol previously described
[16].
RT-PCR reaction analysis
Total RNA from mature adipocytes and SVF were
extracted using the RNAeasy Mini Kit from Qiagen
(Barcelona, Spain). RNA was quantified using the Nano-
Drop®Spetrophotometer ND-1000. RT-PCR was used to
measure mRNA expression levels of target genes. Ali-
quots of 0.5 μg of total RNA (in a final volume of 10
μL) were denatured at 90°C for 1 min and then reverse-
transcribed to cDNA using MuLV reverse transcriptase
(Applied Biosystem, Madrid, Spain) at 42°C for 60 min,
with a final step of 5 min at 99°C in a Perkin-Elmer
9700 Thermal Cycler (PerkinElmer, Wellesley, MA).
RT-PCR was completed using the LightCycler System
with SYBR Green I (Roche Diagnostic Gmbh, Man-
nheim, Germany). Primer sequences are listed in Table
1. All primers were purchased from Sigma (Madrid,
Spain). Each PCR was performed in a total volume of 8
μL, made from diluted cDNA template, forward and
reverse primers (1 μmol/L each), and SYBR Green I
master mix (including Taq polymerase, reaction buffer,
MgCl2, SYBR Green I dye, and dNTP mix). In order to
verify the purity of the products, a melting curve was
produced after each run by increasing the temperature
of the reaction mixtures up to 95°C, by 0.1°C/s, starting
at 55°C for 10 s. PCR products were also analyzed by
electrophoresis in an ethidium bromide-stained agarose
gel to check that a single amplicon of the expected size
was indeed obtained.
The relative quantification of each target gene (adipo-
nectin, leptin, MPC1, Emr1, IL-6, TNFa,a n diNOS)w a s
calculated based on efficiency and the crossing point
deviation of an unknown sample versus a control, and
normalized by the expression of the reference house-
keeping gene 18S rRNA [17]. Results from CLA treated
groups were expressed as fold induction relative to the
control group. Data were expressed using both mRNA
concentration in each cellular fraction and total mRNA
content.
Statistical analysis
Data are presented as means ± SEM. Repeated-measures
ANOVA was used to determine differences in body
weight gain. One-way ANOVA was used to determine
the significance of the differences in tissue weights,
plasma concentrations of metabolites, mRNA abundance
and levels with different treatments. If there was a signifi-
cant difference, a Least Significant Difference (LSD) test
was used to determine the particular effect that caused
that difference. P < 0.05 was statistically significant, and
different superscripts discriminate differences between
groups. The analysis was performed using the SPSS pro-
gram for Windows version 14 (SPSS, Chicago, IL, USA).
Results
Body and tissue weights and energy intake
After 30 d of CLA treatment, no evident effects on the
rate of body weight gain were observed (Figure 1). Since
circulating leptin levels are proportional to overall adi-
pose mass rather than body weight, plasma leptin con-
centration was also determined at this time-point and no
differences between groups were found. As previously
suggested, fat content in diet could determine the effec-
tiveness of CLA doses [18]. Therefore, considering that
the amount of CLA administered didn’ts e e mt oh a v ea
significant effect on body fat content, we decided to dou-
ble the doses from day 30 onwards. Accordingly, mice
started to receive 251 mg CLA/kg body weight and day
in CLA1 group and 414 mg CLA/kg body weight and day
in CLA2 group until the end of the experiment.
Then, body weight reached at the end of the treatment
was still not statistically different between control and
CLA supplemented animals. However, lower body weight
gain was observed during the treatment by CLA (Figure
1) (repeated-measures ANOVA: P < 0.05, effect of time ×
treatment) and the effects were more noticeable from day
30 onwards, with doubled doses, and in the CLA2 group,
in which the increase in body weight gain for the last 30
days of study was 39% lower than in control group.
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consumed were found between groups (2428 ± 119 in con-
trol, 2263 ± 104 in CLA1 and 2382 ± 5 kJ/animal in CLA2
group, each group n = 8). Adiposity was significantly
reduced with the highest dose of CLA (47% lower vs. con-
trol group, P < 0.001) and weights of epididymal, retroperi-
toneal and brown adipose tissue were significantly lower in
this group (Table 2). This effect was more marked in retro-
peritoneal (67% lower) and epididymal (56% lower) depots
than in brown adipose tissue (20% lower) while mesenteric
d e p o tw a sn o ta f f e c t e da ta l l .C L A 1g r o u pe x p e r i e n c e do n l y
a significant reduction in retroperitoneal fat depot.
Liver weight and triglyceride content
There was no effect of CLA treatment on the weight of
liver (0.876 ± 0.03 in control, 0.932 ± in CLA1 and
0.970 ± 0.052 g in CLA2 group, n = 8). No changes in
hepatic triglyceride content were observed after CLA
treatment (50.49 ± 2.98 in control, 55.66 ± 2.12 in
CLA1 and 50.72 ± 3.36 mg triglycerides/g liver, n = 8).
Table 1 Gene-specific primer sequences used in real-time PCR amplification
Gene Primer sequence (5’ ! 3’) Product length (bp) Primer efficiency
Adiponectin F: GCTCAGGATGCTACTGTTG 255 1.9
R: TCTCACCCTTAGGACCAAG
Leptin F: TTGTCACCAGGATCAATGACATTT 106 1.9
R: GACAAACTCAGAATGGGGTGAAG
MCP1 F: GCTCTCTCTTCCTCCACCAC 208 1.8
R: GCTTCTTTGGGACACCTGCT
Emr1 F: TTTCCTCGCCTGCTTCTTC 222 1.8
R: CCCCGTCTCTGTATTCAACC
IL-6 F: TGGGAAATCGTGGAAATGAG 249 1.9
R: GAAGGACTCTGGCTTTGTCTT
TNFa F: CGTCGTAGCAAACCACCAA 145 1.7
R: GAGAACCTGGGAGTAGACAAGG
iNOS F: GGCAGCTACTGGGTCAAAGA 172 1.8
R: TCTGAGGGCTGACACAAGG
18S F: CGCGGTTCTATTTTGTTGGT 219 1.9
R: AGTCGGCATCGTTTATGGTC
F, forward; R, reverse. Target genes: adiponectin; leptin; monocyte chemotactic protein-1 (MCP1); epidermal growth factor module-containing mucin-like receptor
1( Emr1); interleukin-6 (IL-6); tumor necrosis factor alpha (TNFa); inducible nitric oxide synthase (iNOS). 18S rRNA was used for normalization.
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Figure 1 Effects of CLA on body weight gain in mice. Mice received a daily dose of CLA equivalent to 3 mg CLA/animal in CLA1 group and
10 mg/animal in CLA2 group for the first 30 d and 6 mg CLA/animal in CLA1 group and 20 mg/animal in CLA2 group for the last 35 d of
treatment. Data are means ± SEM of 8 mice. Repeated-measures analysis of variance of body weight gain associated with CLA treatment was
significant with respect to the control (P < 0.05). No differences between doses were found. x2dose: indicates the point from which the double
dose was given.
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Plasma glucose, adiponectin and leptin concentrations
were not different between groups after 30 days of treat-
ment (Table 3).
Adiponectin and leptin concentrations were signifi-
cantly decreased with the highest dose of CLA at the
end of the study (Table 3). No significant differences in
circulating resistin concentration were found between
groups and the same was seen concerning plasma trigly-
cerides. NEFA concentration decreased in both CLA
treated groups while plasma glycerol concentration
decreased only in CLA2 group (Table 3). Insulin con-
centration increased with CLA treatment (P <0 . 0 1 )
(16% and 25% in CLA1 and CLA2 group, respectively)
and CLA2 group presented higher fasting glucose con-
centration than CLA1 (P < 0.05) (Table 3).
ITT and calculated indices
No differences between groups were observed in the
ITT carried out at day 30 of treatment, either measuring
the change in plasma glucose concentration (data not
s h o w n )o rt h ea r e au n d e rt h ec u r v e( 7 5 6±4 1i nc o n -
t r o l ,7 9 4±4 6i nC L A 1a n d9 1 3±8 1m m o lg l u c o s e · -
min/L in CLA2 group, n = 5-6). The calculated
homeostatic model assessment for insulin resistance
(HOMA-IR) was higher in CLA2 group at the end of
the study (Table 3) (P < 0.001). However, the calculated
revised quantitative insulin sensitivity check index (R-
QUICKI) showed no differences between groups.
Gene expression in adipocytes and SVF
Adiponectin and leptin mRNAs were dose-dependently
reduced by CLA treatment in mature adipocytes (P <
Table 2 Adipose tissue weights in mice supplemented with CLA
Control CLA1 CLA2
White adipose tissues
Epididymal (g) 0.644 ± 0.048
a 0.628 ± 0.057
a 0.284 ± 0.022
b
Retroperitoneal (g) 0.212 ± 0.030
a 0.129 ± 0.015
b 0.069 ± 0.007
c
Mesenteric (g) 0.250 ± 0.020 0.262 ± 0.022 0.233 ± 0.018
Sum (g) 1.107 ± 0.089
a 1.018 ± 0.091
a 0.586 ± 0.042
b
Brown adipose tissue (g) 0.118 ± 0.007
a 0.126 ± 0.007
a 0.095 ± 0.003
b
Weights of white adipose tissues from different anatomical locations and brown adipose tissue of mice treated with a daily dose of CLA equivalent to 3 mg CLA/
animal in CLA1 group and 10 mg/animal in CLA2 group for the first 30 d and 6 mg CLA/animal in CLA1 group and 20 mg/animal in CLA2 group for the
subsequent 35 d of treatment. Data are expressed in grams and are the means ± SEM of 8 mice. Means in a row without a common letter differ, P < 0.05
(ANOVA followed by LSD test).
Table 3 Effects of CLA treatment on plasma concentration of metabolites in mice
Control CLA1 CLA2
30 days of treatment
Glucose (mmol/L) 8.2 ± 0.2 7.6 ± 0.2 8.0 ± 0.3
Adiponectin (μg/ml) 13.41 ± 1.35 13.78 ± 0.67 13.64 ± 1.14
Leptin (ng/ml) 3.11 ± 0.88 2.08 ± 0.35 1.62 ± 0.27
65 days of treatment
Glucose (mmol/L) 4.33 ± 0.23
ab 4.15 ± 0.14
a 4.90 ± 0.21
b
Adiponectin (μg/ml) 17.33 ± 1.05
a 16.87 ± 0.84
a 11.64 ± 1.25
b
Leptin (ng/ml) 2.09 ± 0.39
a 2.57 ± 0.45
a 0.45 ± 0.10
b
Resistin (ng/ml) 15.27 ± 1.04 15.90 ± 0.91 14.32 ± 0.93
NEFAs (mg/dl) 26.00 ± 1.80
a 19.36 ± 1.96
b 14.44 ± 1.47
b
Glycerol (mg/ml) 0.19 ± 0.02
a 0.15 ± 0.02
a 0.06 ± 0.02
b
Triglycerides (mg/ml) 0.61 ± 0.03 0.60 ± 0.05 0.51 ± 0.08
Insulin (pmol/L) 15.95 ± 0.35
a 18.50 ± 0.87
b 19.89 ± 0.80
b
Leptin/adiponectin ratio 0.12 ± 0.02
a 0.16 ± 0.03
a 0.04 ± 0.01
b
HOMA-IR 0.42 ± 0.02
a 0.47 ± 0.02
a 0.60 ± 0.04
b
R-QUICKI 0.46 ± 0.01 0.48 ± 0.01 0.49 ± 0.01
At 30 d of treatment and after 3 h fast, glucose, adiponectin and leptin plasma concentrations were determined from tail blood samples. The rest of plasmatic
metabolites were determined at the end of the study (65 days of treatment) after 10 h fast and from blood samples collected by cardiac puncture. Data are
means ± SEM of 8 mice at 65 d of treatment; of 3-8 mice for leptin and adiponectin on day 30 and of 7 mice for glucose on day 30. Means in a row without a
common letter differ, P < 0.05 (ANOVA followed by LSD test).
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highest dose with respect to both control and CLA1
groups, while it was increased in adipocytes from CLA1
with respect to both control and CLA2 groups (Table
4).
No effects of CLA treatment on iNOS and MCP1
gene expression were appreciated on the SVF (Table 4).
The highest CLA dose achieved a reduction in IL-6
gene expression (P < 0.05) and an increase in Emr1 (P <
0.001) with respect to both control and CLA1 groups.
Meanwhile TNFa gene expression was increased in SVF
of CLA2 animals with respect to the control group (P <
0.01) (Table 4).
Interestingly, CLA treatment showed a tendency to
increase RNA yield, particularly in the adipocyte fraction
where it attained statistical significance (Table 5). This is
of special relevance because of the minor size of adipose
depots in mice treated with CLA. For this reason, gene
expression in mature adipocytes (Figure 2) and SVF
(Figure 3) was referred to the total RNA content of the
respective epididymal fraction in order to attain a closer
physiological view of the endocrine function of the fat
depot and its potential for macrophage recruitment.
Under this novel perspective, gene expression data
showed a slightly different profile than above, whereas
MCP1 adipose gene expression was unaffected, adipo-
nectin and leptin decreased only with the highest dose
of CLA in mature adipocytes (Figure 2), therefore, total
contribution of mature adipocytes reflected in a better
way, the plasma levels of the two adipocytokines. Con-
cerning the expression profile in cells from the SVF, the
decrease in IL-6 gene expression with the highest dose
was maintained (Figure 3) and the same tendency was
now evident in CLA1 group. Furthermore, TNFa and
Emr1 gene expression were not affected by CLA treat-
ment, while iNOS gene expression decreased with both
d o s e so fC L A .Ar e d u c t i o no fM C P 1g e n ee x p r e s s i o n ,
although not statistically significant, was observed with
CLA2 dose in relation to control group.
Discussion
Mice constitute an animal model particularly sensitive to
potential deleterious side effects of CLA such as insulin
resistance, hyperinsulinaemia and liver steatosis [7-11].
Most previous studies have made use of enriched diets,
containing between 0.5 and 1.5% CLA (for review, see
[6,19]) which in this animal model, supply a daily dose
around 50 times higher than those successfully used in
human trials [12,20]. Therefore, the adverse side effects
seen in mice could be due to the use of large doses
rather than the use of optimal doses which would
reduce body fat content without showing any of the
adverse effects reported. According to this hypothesis,
we have previously reported that mice fed with a stan-
dard-fat diet and treated with moderate doses of the
commercial product Tonalin® - an equimolar mix of cis-
9, trans-11 and trans-10, cis-12 CLA isomers - show
reduced body weight gain and lower fat depots without
any of the adverse effects associated with CLA treat-
ments [16]. Therefore, similar doses of the CLA mixture
Table 4 Relative expression of target mRNAs in mature adipocytes and stromal vascular fraction in mice treated with
CLA
Control CLA1 CLA2
Mature adipocytes
Adiponectin 1.00 ± 0.05
a 0.72 ± 0.04
b 0.39 ± 0.02
c
Leptin 1.00 ± 0.07
a 0.57 ± 0.05
b 0.16 ± 0.01
c
MCP1 1.00 ± 0.09
a 1.28 ± 0.10
b 0.71 ± 0.06
c
Stromal Vascular Fraction
IL-6 1.00 ± 0.09
a 0.96 ± 0.10
a 0.61 ± 0.04
b
TNFa 1.00 ± 0.11
a 1.47 ± 0.18
ab 1.87 ± 0.30
b
iNOS 1.00 ± 0.08 0.81 ± 0.05 1.24 ± 0.20
Emr1 1.00 ± 0.11
a 1.46 ± 0.11
a 2.64 ± 0.28
b
MCP1 1.00 ± 0.13 1.40 ± 0.18 1.23 ± 0.11
Epididymal adipose tissue was digested by collagenase and then separated into mature adipocytes and stromal vascular fraction. Expression levels of target
genes of each fraction were measured by real time PCR and normalized by the internal housekeeping gene 18S rRNA. The results, mean ± SEM of 6-8 mice/
group, are expressed as fold induction over control group. Means in a row without a common letter differ, P < 0.05 (ANOVA followed by LSD test).
Table 5 Total RNA yields obtained from mature
adipocytes and stromal vascular fraction in CLA treated
mice
RNA yield (μg RNA/g of epididymal
depot)
Control CLA1 CLA2
Mature adipocytes 5.5 ± 0.6
a 9.8 ± 0.7
b 8.8 ± 0.8
b
Stromal vascular fraction 8.8 ± 0.4 6.1 ± 1.2 11.0 ± 2.5
Epididymal adipose tissue was digested by collagenase and then separated
into mature adipocytes and stromal vascular fraction. RNA extracted from
each fraction was quantified and referred per gram of epididymal adipose
tissue weight. Data are expressed in μg RNA per g of epididymal tissue and
are the means ± SEM of 7-8 mice/group. Means in a row without a common
letter differ, P < 0.05 (ANOVA followed by LSD test).
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Page 6 of 10were used in the current study, in order to assess their
efficacy in animals with susceptibility to diet-induced
body weight gain and exposure to a high-fat diet.
A slight effect on reducing body weight gain with CLA
treatment was observed by the end of the study. In fact,
the lower dose of CLA reduced only the retroperitoneal
fat depot, which seems to be the most sensitive to CLA
effects [16,21,22], whereas the highest dose also reduced
the size of the epididymal depot, supporting the fact
that CLA effects are tissue-specific as seen in humans
[23]. In brief, the administration of CLA reduces the
gain of weight and fat observed in control group, sug-
gesting that the administration of CLA may mitigate the
effects of an obesity-promoting environment.
A reduction in adiposity is usually associated with
improved insulin sensitivity and plasma adipocytokine
profile, but this is not so clear when the fat loss is
caused by CLA supplementation. While some studies
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Figure 2 Contribution of mature adipocytes isolated from epididymal fat depot to the expression of target mRNA in CLA treated
mice. Epididymal adipose tissue was digested by collagenase and then separated into mature adipocytes and stromal vascular fraction.
Expression levels of target genes of each fraction were measured by real time PCR and normalized by the internal housekeeping gene 18S rRNA.
Expression data in adipocytes, derived from equal amount of RNA (Table 4), were referred to the total RNA content in the adipocyte fraction.
Data, means ± SEM of 7-8 mice, are represented as fold induction over control group. Mean values with unlike letters are significantly different
(P < 0.01); ANOVA followed by LSD test.
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Figure 3 Contribution of SVF cells isolated from epididymal fat depot to the expression of target mRNA in CLA mice. Epididymal
adipose tissue was digested by collagenase and then separated into mature adipocytes and stromal vascular fraction. Expression levels of target
genes of each fraction were measured by real time PCR and normalized by the internal housekeeping gene 18S rRNA. Expression data in the
stromal vascular fraction (SVF), derived from equal amount of RNA (Table 4) were referred to the total RNA content in SVF. Data, means ± SEM
of 6-8 mice, are represented as fold induction over control group. Mean values with unlike letters are significantly different (P < 0.01); ANOVA
followed by LSD test.
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Page 7 of 10have shown beneficial effects in rat models [24-26] and
in mice [16,25], several have observed harmful effects of
CLA on insulin sensitivity, particularly in mice
[8,9,11,14,27]. Here, the higher dose of CLA caused a
reduction in both, plasma leptin and adiponectin con-
centrations (Table 3); which could be attributed to the
reduction of fat depots, the main synthesizing organs,
and also to the reduction in absolute terms of its gene
expression (Figure 2). Deregulation in the production of
these two adipocytokines has been observed in both
obese and lipodystrophy states [28] and has been pro-
posed to contribute to the impairment of insulin sensi-
tivity [8]. Lipodystrophy may occur in mice treated with
high doses of CLA, due to its higher sensitivity to the
CLA-induced reduction in body fat [11,29,30]. In these
conditions, the drastic plasma reduction of leptin and
adiponectin associated with CLA treatment, induces
fatty liver and hyperinsulinaemia, not through the direct
induction of hepatic lipid synthesis and insulin resis-
tance, but because of the scarcity of the adipose tissue
[30]. Interestingly, the doses of CLA tested here were
associated with an important reduction in body fat, but
without reaching the lipodystrophy status. Although fat
loss was accompanied by a moderate degree of hyperin-
sulinaemia (25% increase) it was far from the 300-400%
increase found in other studies using higher doses
[8,10,31]. No hepatic steatosis or liver enlargement was
observed and it was accompanied by maintenance of
insulin sensitivity, as particularly indicated by ITT and
R-QUICKI, despite the higher HOMA-IR index. In fact,
R-QUICKI has been described as more accurate than
HOMA-IR, as surrogate marker to assess insulin sensi-
tivity incorporating the level of fasting NEFA together
with insulin and glucose levels [32,33]. In consequence,
the decreased circulating concentrations of leptin and
adiponectin promoted by CLA treatment were consis-
tent with maintenance of glucose-insulin homeostasis,
as seen in normal-fat fed mice, where CLA causes fat
loss, decreases leptin and goes in hand with lower adi-
ponectin levels, reaching a novel set point between these
two circulating adipocytokines, which is associated with
the maintenance of insulin sensitivity and a decrease in
the expression of inflammatory markers in adipose tis-
sue [16]. The relative amount of these two adipocyto-
kines is likely to be more important than their absolute
concentrations. Thus, for example, lipoatrophy-asso-
ciated insulin resistance can be completely reversed by
the combination of adiponectin and leptin, but only par-
tially by either adiponectin or leptin alone [28].
Concerning the effects of CLA on the inflammatory
profile of adipose tissue, supplementation with CLA
may induce inflammatory gene expression in adipocytes
and promote macrophage infiltration into adipose tissue
showing isomer specific dependence as seen for trans-
10, cis-12 CLA [13,14,34,35] but not for cis-9, tras-11
CLA [15] either for the mix of both isomers under nor-
mal fat diet [16].
In accordance with the minor outcome on fat reduc-
tion, minor effects on gene expression were also seen in
the group that received the lowest dose of CLA, whereas
the highest dose of CLA had a major impact on adipose
and SVF gene expression profile. Expression of MCP1, a
chemoattractant protein which promotes recruitment of
macrophages into adipose tissue and, therefore, inflam-
matory responses in obesity [36], was decreased in adi-
pocytes (Figure 2) and showed the same tendency in
S V Fo fC L A 2g r o u p( F i g u r e3 ) .T h i sw a sa c c o m p a n i e d
b yar e d u c t i o ni nt h ee x p r e s s i o no fp r o - i n f l a m m a t o r y
mediators such as IL-6 and iNOS and unaltered expres-
sion of both TNFa and the macrophage marker Emr1.
Proinflammatory cytokines have been shown to promote
adipocyte delipidation and impair insulin signaling
[13,37,38]. In fact, trans-10, cis-12 CLA was reported to
induce IL-6 secretion which seemed to be, at least in
part, responsible for the isomer-mediated suppression of
PPARg target gene expression and impairment of insulin
sensitivity in mature human adipocytes [13]. Collec-
tively, our data suggested that, particularly at the highest
dose tested, CLA supplementation may ameliorate the
inflammatory state in obesity, attenuating macrophage
infiltration and/or activation into adipose tissue, as seen
in animals fed with a standard-fat diet [16] but not with
higher doses [10] or by administration of the single
trans-10, cis-12 CLA isomer [14].
Conclusion
In conclusion, an equimolar mix of the two main CLA
i s o m e r s ,a tam o d e r a t ed o s e ,w a sa b l et om i t i g a t eb o d y
fat accumulation by high fat feeding, and in contrast to
studies with larger doses of CLA and particularly with
pure trans-10, cis-12 isomer, this was associated with an
improvement of the lipid profile in plasma and mainte-
nance of insulin sensitivity, despite a moderate degree of
hyperinsulinaemia, which was far from the 3-4 fold
increase observed with higher doses and trans-10, cis-12
isomer. Furthermore, in our experimental conditions,
CLA seems to ameliorate the inflammatory profile in
adipose tissue, causing a reduction in the expression of
MCP1, the main macrophage recruitment factor, and a
decrease in the expression of the pro-inflammatory
mediators iNOS and IL-6.
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